Literature DB >> 21885953

Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.

Emmanuel J Favaloro1.   

Abstract

von Willebrand disease (VWD) is considered to be the most common inherited bleeding disorder. VWD is diagnosed following a clinical and physical review, with personal and familial evidence of (primarily mucocutaneous) bleeding, and confirmed by laboratory testing. The latter typically entails initial plasma testing of factor VIII coagulant, von Willebrand factor (VWF) protein ('antigen') and VWF function which has classically been assessed using the ristocetin cofactor (VWF:RCo) assay. More recent attention has focussed on other functional VWF assays, such as collagen binding and so-called 'VWF activity' assays, as possible replacements to the VWF:RCo, or as supplementary tests of VWF 'function'. Additional laboratory testing can comprise a battery of confirmatory and VWD-type assisting assays, including VWF:multimer and von Willebrand factor VIII binding. This review aims to update knowledge of current VWD diagnostics with a particular emphasis on 'functional' VWF assays.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21885953     DOI: 10.1097/MBC.0b013e32834a7e01

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  10 in total

Review 1.  Perils, problems, and progress in laboratory diagnosis of von Willebrand disease.

Authors:  Veronica H Flood
Journal:  Semin Thromb Hemost       Date:  2013-12-12       Impact factor: 4.180

Review 2.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

3.  Misfolding of vWF to pathologically disordered conformations impacts the severity of von Willebrand disease.

Authors:  Alexander Tischer; Pranathi Madde; Laurie Moon-Tasson; Matthew Auton
Journal:  Biophys J       Date:  2014-09-02       Impact factor: 4.033

4.  Clinical and laboratory phenotype variability in type 2M von Willebrand disease.

Authors:  A L Doruelo; S L Haberichter; P A Christopherson; L N Boggio; S Gupta; S R Lentz; A D Shapiro; R R Montgomery; V H Flood
Journal:  J Thromb Haemost       Date:  2017-06-23       Impact factor: 5.824

Review 5.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

6.  De novo mutation and somatic mosaicism of gene mutation in type 2A, 2B and 2M VWD.

Authors:  Ming-Ching Shen; Ming Chen; Gwo-Chin Ma; Shun-Ping Chang; Ching-Yeh Lin; Bo-Do Lin; Han-Ni Hsieh
Journal:  Thromb J       Date:  2016-10-04

7.  Establishment and characterization of a new and stable collagen-binding assay for the assessment of von Willebrand factor activity.

Authors:  Y Ni; J Nesrallah; M Agnew; F J Geske; E J Favaloro
Journal:  Int J Lab Hematol       Date:  2012-10-29       Impact factor: 2.877

8.  Von-Willebrand disease presenting as intractable epistaxis after nasal polypectomy.

Authors:  Jeong Jin Park; Chang-Hoon Kim; Jeung-Gweon Lee; Hyung-Ju Cho
Journal:  Case Rep Otolaryngol       Date:  2014-08-25

9.  A genetically-engineered von Willebrand disease type 2B mouse model displays defects in hemostasis and inflammation.

Authors:  Frédéric Adam; Caterina Casari; Nicolas Prévost; Alexandre Kauskot; Cécile Loubière; Paulette Legendre; Christelle Repérant; Dominique Baruch; Jean-Philippe Rosa; Marijke Bryckaert; Philip G de Groot; Olivier D Christophe; Peter J Lenting; Cécile V Denis
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

10.  Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.

Authors:  Johannes C Nossent; Warren D Raymond; Gro Østli Eilertsen
Journal:  Lupus Sci Med       Date:  2016-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.